Dacarbazine

Evidence Level: L5

Predicted Indications: 1

Dacarbazine

Pharmacist Assessment Report

Dacarbazine: From Hodgkin Lymphoma and Metastatic Melanoma to Upper Aerodigestive Tract Neoplasm

One-Sentence Summary

Dacarbazine is an alkylating chemotherapy drug originally used for metastatic melanoma and Hodgkin lymphoma. The TxGNN model predicts it may be effective for upper aerodigestive tract neoplasm, but no clinical trials are registered for this indication, and the 20 publications compiled are mostly indirect: reviews, case reports, and studies of related tumours.

Quick Overview

Item	Content
Original Indication	Metastatic melanoma; Hodgkin lymphoma (including classic Hodgkin lymphoma)
Predicted New Indication	Upper aerodigestive tract neoplasm
TxGNN Prediction Score	0.9926
Evidence Level	L5 (no direct clinical studies; the data’s preliminary grading was L4, but only indirect and mechanistic-adjacent literature exists)
Canada Market Status	Marketed (marketed DINs: 1 of 1)
Number of DINs	1 (marketed: 1)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not currently available in the data compiled for this report. Based on general knowledge, dacarbazine is an alkylating agent. It is converted to an active metabolite (MTIC) that methylates DNA, and its efficacy in metastatic melanoma and Hodgkin lymphoma is established.

Melanoma and Hodgkin lymphoma can both involve the head and neck or upper aerodigestive mucosa. Examples include mucosal melanoma metastases and extranodal or nodal head and neck Hodgkin lymphoma. The high TxGNN score likely reflects these shared disease neighbourhoods rather than proven activity against primary upper aerodigestive tract carcinomas such as squamous cell carcinoma.

Indirect signals also come from dacarbazine-containing regimens in other neuroendocrine or neural-crest tumours, such as medullary thyroid carcinoma and malignant paraganglioma. No direct mechanistic evidence supports efficacy in primary upper aerodigestive tract neoplasms.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

The publications below were retrieved for this prediction. None is a trial of dacarbazine in primary upper aerodigestive tract cancer. Their relevance has not yet been reviewed.

PMID	Year	Type	Journal	Key Findings
41481311	2026	RCT (Phase 3)	JAMA Oncol	Toripalimab vs dacarbazine as first-line therapy in advanced acral melanoma. Dacarbazine is the on-label comparator, so this is not the target indication.
7826911	1994	Clinical study	Ann Oncol	Small study of dacarbazine plus 5-FU in advanced medullary thyroid cancer, a neuroendocrine tumour.
20564093	2010	Retrospective cohort	Cancer	Characteristics and outcomes of Hodgkin lymphoma involving head and neck sites.
31621203	2019	Prospective observational	Cancer Med	Carbon-ion radiotherapy plus dacarbazine, nimustine and vincristine (DAV) in 21 patients with head and neck mucosal melanoma.
34654328	2024	Cohort	Ear Nose Throat J	Six patients with head and neck malignant paragangliomas; clinical, genetic and treatment features.
11815960	2002	Preclinical	Cancer	In mouse xenografts of medullary thyroid carcinoma, dacarbazine was effective alone and combined with radioimmunotherapy.
20627492	2010	Review	Clin Oncol	Review of medullary thyroid carcinoma.
20138008	2010	Review	Transfus Apher Sci	Review of HIV-associated Hodgkin lymphoma.
12113649	2002	Review	Am J Clin Dermatol	Review of current melanoma management.
12845209	2003	Case report	Onkologie	Stage IV melanoma with mucosal metastases to the oesophagus, stomach, bladder and tonsil.

Canada Market Information

DIN	Product Name	Dosage Form	Approved Indication
02241445	DACARBAZINE FOR INJECTION BP	Not specified	Not specified

Cytotoxicity

Item	Content
Cytotoxicity Classification	Conventional cytotoxic (alkylating agent)
Myelosuppression Risk	High. Knowledge-graph contraindications include thrombocytopenia, leukopenia and anaemia, which indicate haematological toxicity.
Emetogenicity Classification	Please refer to the package insert warnings and precautions
Monitoring Items	CBC with differential, liver function, renal function
Handling Protection	Must follow cytotoxic drug handling regulations

Safety Considerations

Disease-level cautions (knowledge graph, not label text): Kidney disease, liver disease, gallbladder disease, hepatic vein thrombosis, Budd-Chiari syndrome, pyoureter, thrombocytopenia, anaemia, macrocytic anaemia and leukopenia.
Drug Interactions: 100 interactions were identified. Only the two with a graded level are listed here: naltrexone (Moderate) and levofloxacin (Minor). Other listed drugs, such as pantoprazole, morphine, metformin, omeprazole, prednisone, simvastatin, ondansetron, aprepitant and palonosetron, have an unknown severity level.

For warnings and contraindications from the label, please refer to the package insert.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction score is high, but there are no clinical trials and no direct evidence in primary upper aerodigestive tract cancers. The literature is indirect, drawn from melanoma, Hodgkin lymphoma and neuroendocrine tumours, and the label-based safety review cannot proceed without the Health Canada package insert.

To proceed, the following is needed:

Health Canada package insert warnings and contraindications (blocking for safety screening)
Mechanism of action data from DrugBank
Clarification of which upper aerodigestive tract tumour types are meant (for example, mucosal melanoma versus squamous cell carcinoma)
Relevance review of the retrieved literature and a search for direct clinical data in the target population
Approved indication text and dosage form for DIN 02241445
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.